Aflatoxin B1 metabolism (WP1262)

'''Aflatoxins''' are naturally occurring [[wikipedia:mycotoxin|mycotoxin]]s that are produced by many species of ''[[wikipedia:Aspergillus|Aspergillus]]'', a [[wikipedia:fungus|fungus]], most notably ''[[wikipedia:Aspergillus flavus|Aspergillus flavus]]'' and ''[[wikipedia:Aspergillus parasiticus|Aspergillus parasiticus]]''. After entering the body, aflatoxins are metabolized by the liver to a reactive intermediate, aflatoxin M1, an [[wikipedia:epoxide|epoxide]]. Aflatoxin B1 is considered the most toxic and is produced by both Aspergillus flavus and Aspergillus parasiticus. Source: [[wikipedia:Aflatoxin|Wikipedia]]
last edited


MaintBot, Thomas, Khanspers, Christine Chichester, and Mkutmon

Cited In


Mus musculus



Pathway Ontology: aflatoxin metabolic pathway


Label Type Compact Identifier
Aflatoxin B1 C8-monoalcohol Metabolite None
Aflatoxin-endo-B1-8,9-epoxide Metabolite None
Akr7a5 GeneProduct ensembl:ENSMUSG00000028743
Cyp1a2 GeneProduct ensembl:ENSMUSG00000032310
AKR7A3 GeneProduct None
Gstt1 GeneProduct ensembl:ENSMUSG00000001663
Gstm1 GeneProduct ncbigene:14862
CYP2A13 GeneProduct None
Aflatoxin B1 exo-8,9-epoxide-GSH Metabolite pubchem.compound:5460816
Ephx1 GeneProduct ensembl:ENSMUSG00000038776
Cyp1a2 GeneProduct ensembl:ENSMUSG00000032310
Aflatoxin B1-6,8-dialcohol Metabolite None
Aflatoxin B1 8,9-dihydrodiol Metabolite None
Aflatoxin B1 dialdehyde Metabolite None
Cyp1a2 GeneProduct ensembl:ENSMUSG00000032310
aflatoxin B1 Metabolite hmdb:HMDB0006552
Aflatoxin B1 exo-8,9-epoxide Metabolite hmdb:HMDB0006558
Aflatoxin M1 Metabolite pubchem.compound:15558498
Aflatoxin B1 C8-monoaldehyde Metabolite None
Aflatoxin M1 epoxide Metabolite None
CYP2A13 GeneProduct None
Aflatoxin B1 C6-monoalcohol Metabolite None
Aflatoxin Q1 Metabolite pubchem.compound:104757
CYP3A4 GeneProduct None
Aflatoxin B1 C6-monoaldehyde Metabolite None
CYP3A4 GeneProduct None


  1. Stewart RK, Smith GB, Donnelly PJ, Reid KR, Petsikas D, Conlan AA, et al. Glutathione S-transferase-catalyzed conjugation of bioactivated aflatoxin B(1) in human lung: differential cellular distribution and lack of significance of the GSTM1 genetic polymorphism. Carcinogenesis. 1999 Oct;20(10):1971–7. PubMed Europe PMC Scholia
  2. Guengerich FP, Cai H, McMahon M, Hayes JD, Sutter TR, Groopman JD, et al. Reduction of aflatoxin B1 dialdehyde by rat and human aldo-keto reductases. Chem Res Toxicol. 2001 Jun;14(6):727–37. PubMed Europe PMC Scholia
  3. Tiemersma EW, Omer RE, Bunschoten A, van’t Veer P, Kok FJ, Idris MO, et al. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):785–91. PubMed Europe PMC Scholia
  4. Guengerich FP, Arneson KO, Williams KM, Deng Z, Harris TM. Reaction of aflatoxin B(1) oxidation products with lysine. Chem Res Toxicol. 2002 Jun;15(6):780–92. PubMed Europe PMC Scholia
  5. Kensler TW, Qian G-S, Chen J-G, Groopman JD. Translational strategies for cancer prevention in liver. Nat Rev Cancer. 2003 May;3(5):321–9. PubMed Europe PMC Scholia
  6. He X-Y, Tang L, Wang S-L, Cai Q-S, Wang J-S, Hong J-Y. Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int J Cancer. 2006 Jun 1;118(11):2665–71. PubMed Europe PMC Scholia
  7. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006 Mar 10;8(1):E101-11. PubMed Europe PMC Scholia
  8. Zhu L-R, Thomas PE, Lu G, Reuhl KR, Yang G-Y, Wang L-D, et al. CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Drug Metab Dispos. 2006 Oct;34(10):1672–6. PubMed Europe PMC Scholia
  9. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol. 2007;47:263–92. PubMed Europe PMC Scholia
  10. Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev. 2008;40(4):553–624. PubMed Europe PMC Scholia